Use of long acting antipsychotics and relationship to newly diagnosed bipolar disorder: a pragmatic longitudinal study based on a Canadian health registry.
Antipsychotics
bipolar disorder
mood stabilisers
schizophrenia
Journal
Therapeutic advances in psychopharmacology
ISSN: 2045-1253
Titre abrégé: Ther Adv Psychopharmacol
Pays: England
ID NLM: 101555693
Informations de publication
Date de publication:
2020
2020
Historique:
received:
01
03
2020
accepted:
18
08
2020
entrez:
25
9
2020
pubmed:
26
9
2020
medline:
26
9
2020
Statut:
epublish
Résumé
There is limited data from large naturalistic studies to inform prescribing of long-acting injectable medication (LAIs). Guidance is particularly rare in the case of primary mood disorders. This study describes prescribing trends of LAIs in 3879 patients in Quebec, Canada, over a period of 4 years. Health register data from the Quebec provincial health plan were reviewed. In this specific registry, 32% of patients who received LAIs drugs for schizophrenia had a confirmed diagnosis of bipolar disorder and 17% had a diagnosis of major depressive disorder. Non-schizophrenia syndromes were preferentially prescribed risperidone long-acting antipsychotic, whereas patients with schizophrenia were prescribed an excess of haloperidol decanoate. Patients with non-schizophrenia disorders prescribed long-acting antipsychotics were more frequently treated in primary care compared with patients with schizophrenia. Data from a large number of patients treated naturalistically in Quebec with long-acting antipsychotics suggests that these compounds, prescribed to treat symptoms of schizophrenia and schizoaffective disorders, were maintained when mood symptoms emerged, even in cases when the diagnosis changed to bipolar disorder. This pragmatic study supports the need to explore this intervention as potential treatment for affective disorders.
Sections du résumé
BACKGROUND
BACKGROUND
There is limited data from large naturalistic studies to inform prescribing of long-acting injectable medication (LAIs). Guidance is particularly rare in the case of primary mood disorders.
METHODS
METHODS
This study describes prescribing trends of LAIs in 3879 patients in Quebec, Canada, over a period of 4 years. Health register data from the Quebec provincial health plan were reviewed.
RESULTS
RESULTS
In this specific registry, 32% of patients who received LAIs drugs for schizophrenia had a confirmed diagnosis of bipolar disorder and 17% had a diagnosis of major depressive disorder. Non-schizophrenia syndromes were preferentially prescribed risperidone long-acting antipsychotic, whereas patients with schizophrenia were prescribed an excess of haloperidol decanoate. Patients with non-schizophrenia disorders prescribed long-acting antipsychotics were more frequently treated in primary care compared with patients with schizophrenia.
CONCLUSION
CONCLUSIONS
Data from a large number of patients treated naturalistically in Quebec with long-acting antipsychotics suggests that these compounds, prescribed to treat symptoms of schizophrenia and schizoaffective disorders, were maintained when mood symptoms emerged, even in cases when the diagnosis changed to bipolar disorder. This pragmatic study supports the need to explore this intervention as potential treatment for affective disorders.
Identifiants
pubmed: 32974000
doi: 10.1177/2045125320957118
pii: 10.1177_2045125320957118
pmc: PMC7493262
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2045125320957118Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: ES has received lecturing fees from Jansen Canada and from Lundbeck, Canada and UAEU. DA has received travel grants from Jansen-Cilag and Servier and sponsorship from Lundbeck. The other authors report no conflict of interest.
Références
JAMA Psychiatry. 2018 Apr 1;75(4):314-315
pubmed: 29490368
Bipolar Disord. 2018 Mar;20(2):97-170
pubmed: 29536616
Biol Psychiatry. 2010 Jul 15;68(2):156-62
pubmed: 20227682
Can J Psychiatry. 2015 Mar;60(3 Suppl 2):S40-7
pubmed: 25886679
Schizophr Res. 2017 May;183:10-21
pubmed: 27866695
J Psychopharmacol. 2016 Jun;30(6):495-553
pubmed: 26979387
Patient Prefer Adherence. 2010 Sep 07;4:325-34
pubmed: 20859459
Epidemiol Psychiatr Sci. 2016 Feb;25(1):21-3
pubmed: 26515607
Bipolar Disord. 2018 Dec;20(8):687-696
pubmed: 30417552
Can J Psychiatry. 2016 Dec;61(12):758-765
pubmed: 27310244
Neuropsychiatr Dis Treat. 2018 Jun 08;14:1475-1492
pubmed: 29922063
Am J Emerg Med. 2017 Aug;35(8):1211.e1-1211.e2
pubmed: 28460810
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2;82:263-271
pubmed: 29122637
Neuropsychopharmacol Rep. 2019 Sep;39(3):238-240
pubmed: 31325244
Can J Psychiatry. 2015 Mar;60(3 Suppl 2):S5-13
pubmed: 25886681
Clin Drug Investig. 2020 May;40(5):459-468
pubmed: 32274654
Schizophr Res. 2018 Apr;194:39-46
pubmed: 28601497
Neuropsychiatr Dis Treat. 2008 Oct;4(5):919-27
pubmed: 19183782
Curr Med Res Opin. 2018 Jan;34(1):41-47
pubmed: 29057674
Bipolar Disord. 2009 Dec;11(8):827-39
pubmed: 19922552
Ther Adv Psychopharmacol. 2018 Jun 22;8(11):287-301
pubmed: 30344996
Trends Neurosci. 2018 Jan;41(1):18-30
pubmed: 29169634
Expert Rev Neurother. 2017 Oct;17(10):1029-1043
pubmed: 28832262
Bipolar Disord. 2018 Nov;20 Suppl 2:25-36
pubmed: 30328222
Eur Neuropsychopharmacol. 2012 Nov;22(11):825-35
pubmed: 22503488
Br J Psychiatry. 2017 Sep;211(3):137-143
pubmed: 28522434
Expert Rev Neurother. 2010 Nov;10(11):1637-58
pubmed: 20977322
CNS Drugs. 2019 May;33(5):431-456
pubmed: 30963507
Schizophr Bull. 2018 Apr 6;44(3):593-602
pubmed: 28981857
JAMA Psychiatry. 2018 Apr 1;75(4):347-355
pubmed: 29490359
J Psychopharmacol. 2015 May;29(5):459-525
pubmed: 25969470
BMC Psychiatry. 2011 Oct 28;11:171
pubmed: 22034906
J Clin Psychopharmacol. 2016 Aug;36(4):355-71
pubmed: 27307187
Neuropsychiatr Dis Treat. 2016 Feb 05;12:279-85
pubmed: 26917961
Can Geriatr J. 2018 Sep 30;21(3):269-273
pubmed: 30271512
J Med Econ. 2018 Feb;21(2):127-134
pubmed: 28895758
Harv Rev Psychiatry. 2018 Jan/Feb;26(1):1-7
pubmed: 29303917